Trial Profile
A Retrospective Study Investigating the Potential Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Timing of PD1 Inhibition with Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Ramucirumab plus Docetaxel (RD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 26 Sep 2018 Results from a cohort of patients who received ramucirumab+docetaxel as third line treatment presented at the 19th World Conference on Lung Cancer
- 26 Sep 2018 Results describing baseline characteristics, treatment patterns, and clinical outcomes among RDP patients subsequently treated with ram+doc in the United States presented at the 19th World Conference on Lung Cancer
- 26 Sep 2018 Results (n=62) presented at the 19th World Conference on Lung Cancer